QI
IBRX icon

QS Investors’s ImmunityBio IBRX Stock Holding History

QS Investors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$279K Buy
+19,500
New +$322K ﹤0.01% 962
2021
Q1 		– Sell
-19,950
Closed -$266K – 1218
2020
Q4 		$266K Hold
19,950
– – ﹤0.01% 1034
2020
Q3 		$139K Buy
+19,950
New +$199K ﹤0.01% 1106

Other funds holding IBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 14.43% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

QS Investors's IBRX Position: Q2 2021 in Review

QS Investors opened a new position in ImmunityBio (IBRX) in Q2 2021: 19,500 shares worth $279K. The stake represents ﹤0.01% of the portfolio and ranks #962 among its holdings. This is a return to the name: QS Investors previously reported a position in IBRX as recently as Q4 2020.

QS Investors first reported a position in IBRX in Q3 2020 and has held it in 3 quarters since. 125 funds tracked by Wall St. Rank hold IBRX as of Q2 2021.

  • QS Investors held 19,500 shares of ImmunityBio worth $279K as of Q2 2021.
  • ImmunityBio was a new QS Investors position in Q2 2021.
  • ImmunityBio made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #962 holding.
  • QS Investors first reported a position in ImmunityBio in Q3 2020 and has held it in 3 quarters since.
  • 125 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.